Sanofi Allegra Switch Approval Triggers Race To Market For Perrigo
This article was originally published in The Pink Sheet Daily
Executive Summary
OTC Allegra could soon face competition from private-label fexofenadine marketed by Perrigo, which acquired U.S. rights from ANDA-filer Teva.